Abstract: A resin composition includes: a compound represented by Formula (1); and a resin, in the formula, A and B each independently represent an aromatic hydrocarbon ring or an aromatic heterocycle, Ra and Rb each independently represent a substituent, m1 represents an integer of 0 to mA, m2 represents an integer of 0 to mB, Y1 and Y2 each independently represent an alkyl group, an aryl group, a group represented by Formula (Y-1), or a group represented by Formula (Y-2), and at least one of Y1 or Y2 represents a group represented by Formula (Y-1) or a group represented by Formula (Y-2).

Abstract: A nonaqueous electrolyte composition for use in a redox flow battery system, comprising: a nonaqueous supporting electrolyte; and a metal ligand complex of formula II: wherein R1, R2, R3, R4 and R6 are each independently H, halogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, or a polyether, wherein R5 is H, alkyl, or substituted alkyl; and M is a transition metal or zinc.

Abstract: The invention relates to a process for preparing a rare-earth organophosphate in the form of a fluid or not very viscous solution that can be used as is for the preparation of a “preformed” catalyst system intended, in particular, for the cis-1,4 stereospecific polymerization of conjugated dienes.

Abstract: Disclosed are a category of platinum compounds having amino- or alkylamino-containing succinato derivatives as leaving group, or pharmaceutically acceptable salts thereof, preparation method thereof, and medicinal compositions containing the compounds. Also disclosed is a use of the compounds in treating cell proliferative diseases, especially cancers. The platinum compounds of the present invention have high water solubility and small toxic side effect.

Abstract: A surface modified lithium titanate and preparation method thereof is provided. In the surface modified lithium titanate, the deactivating groups distributed on the surface of the lithium titanate are —O—P—RR?R?, —O—P—(OR)R?R?, —O—P—(OR)(OR?)R?, and —O—P—(OR)(OR?)(OR?), where R, R? and R? are identical or different C1˜C8 alkyl or alkenyl groups. The deactivating groups are bonded to the lithium titanate via a bond or a bridge. The exemplary surface modified lithium titanate can effectively lower its catalytic activity, reduce the gassing of lithium ion batteries, and therefore improve the high temperature storage and high temperature cycle performance of lithium titanate batteries. The exemplary preparation method is simple, has great repeatability, a low cost, low pollution to the environment, and is suitable for industrial production.

Abstract: The invention provides a surface-modified zirconia nanocrystal particle, wherein the surface of the zirconia nanoparticle is modified by organic sulfonyloxy groups, and a method of producing a zirconia nanocrystal particle whose surface is modified by carbonyloxy groups, organic phosphoryloxy groups or aryloxy groups. This makes it possible a highly stable surface-modified zirconia nanocrystal particle having a solvent dispersibility by a simple method. Further, it is possible to the surface-modified zirconia nanocrystal particle of the invention is equipped with a surface modifier having a structure that can be easily substituted with a desired functional group according to use. Furthermore, it is possible to the method of producing the surface-modified zirconia nanocrystal particle which is capable of easily producing that.

Abstract: An organic electrolyte solution including a metal-ligand coordination compound, wherein the ligand is an organic phosphate compound.

Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

Abstract: A process for preparing a rare-earth organophosphate in the form of a gel that can be used as is for the preparation of a “preformed” catalyst system intended, in particular, for the cis-1,4 stereospecific polymerization of conjugated dienes.

Abstract: Solutions of rare-earth organophosphates in an organic solvent are prepared by reacting, in such solvent, a rare-earth compound selected from among the rare-earth oxides, hydroxides, carbonates and hydroxycarbonates with an organophosphorus acid and in the presence of a reaction promoter selected from among water, nitric, hydrochloric, acetic, formic and propionic acids and the rare-earth salts of these acids; utilizing a reaction promoter simplifies the method, reduces the reaction time and provides a solution in which the residual solids content may be low.

Abstract: Provided herein are analog and derivative compounds of inositol hexakisphosphate effective to treat a Clostridium difficile infection and to neutralize the bacterial toxins produced by the same. In addition, methods of treating the C. difficile infection and for neutralizing its toxins with the compounds are provided.

Abstract: A lubricant additive produced by various processes, including mixing an organophosphate and an organofluorine compound, reacting an organophosphate and an organofluorine compound, reacting a fluorinated organophosphate and an organofluorine compound (with or without molybendum disulfide), or reacting an organophosphate, a metal halide and an organofluorine compound (with or without molybendum disulfide), to produce a reaction mixture comprising the lubricant additive. Also, a lubricant produced by various processes, including mixing an organophosphate and an organofluorine compound, reacting an organophosphate and an organofluorine compound, reacting a fluorinated organophosphate and an organofluorine compound (with or without molybendum disulfide), or reacting an organophosphate, a metal halide and an organofluorine compound (with or without molybendum disulfide), and adding at least a portion of the reaction mixture to a lubricant base.

Abstract: Disclosed is a low-phosphorous lubricant produced by a process comprising forming a lubricant additive by reacting metal halide and organophosphate together to form a reaction mixture, the metal halide participating as a reactant, and adding at least a portion of the reaction mixture to a lubricant base comprising from about 0.01 weight percent phosphorous to about 0.1 weight percent phosphorous.

Abstract: A lubricant additive produced by the process comprising mixing a metal halide with an organophosphate, the metal halide participating as a reactant and reacting the metal halide and the organophosphate to produce a reaction mixture comprising the lubricant additive. Also disclosed is a lubricant produced by the process comprising forming a lubricant additive by reacting metal halide and organophosphate together to form a reaction mixture, the metal halide participating as a reactant, and adding at least a portion of the reaction mixture to a lubricant base.

Abstract: The disclosures of the Specification provide an oligonucleotide derivative suited to practical use, as well as a fluorescent dye cluster and use therefor. The disclosures of the Specification use a labeling agent comprising a plurality of nucleotide derivative units represented by Formula (1) below: (where, Z represents a nitrogen atom or CH, Y represents an uncondensed aromatic hydrocarbon group or condensed polycyclic hydrocarbon group, X1 represents O, S or Se, and X2 represents SH (or S?), S or Se?, a CI-4 alkyl or a morpholino group.

Abstract: The invention provides a surface-modified zirconia nanocrystal particle, wherein the surface of the zirconia nanoparticle is modified by organic sulfonyloxy groups, and a method of producing a zirconia nanocrystal particle whose surface is modified by carbonyloxy groups, organic phosphoryloxy groups or aryloxy groups. This makes it possible a highly stable surface-modified zirconia nanocrystal particle having a solvent dispersibility by a simple method. Further, it is possible to the surface-modified zirconia nanocrystal particle of the invention is equipped with a surface modifier having a structure that can be easily substituted with a desired functional group according to use. Furthermore, it is possible to the method of producing the surface-modified zirconia nanocrystal particle which is capable of easily producing that.

Abstract: An object of the present invention is to provide an antibacterial medical equipment which has sufficient antibacterial activity in vivo and is excellent in compatibility with living tissues, and also can maintain antibacterial activity over a long period and has high safety. An antibacterial medical equipment characterized in that inositol phosphate is bonded to a Ca compound of a medical equipment whose surface is at least coated with a layer of the Ca compound, or a medical equipment comprising the Ca compound. The antibacterial medical equipment as described above, wherein silver ions are bonded to the inositol phosphate. A method for producing an antibacterial medical equipment, which comprises bringing a medical equipment whose surface is at least coated with a layer of a Ca compound, or a medical equipment comprising a Ca compound into contact with an aqueous solution of inositol phosphate to obtain an antibacterial medical equipment in which inositol phosphate is bonded to the Ca compound.

Abstract: Provided is a phosphorus molybdenum amine compound, represented by the following general formula (I). where R1 to R6 each independently represent a hydrogen atom or a hydrocarbon group and p represents a number of 1 to 5, provided that all of R1 to R6 are can not all be hydrogen atoms at the same time and the phosphorus molybdenum compound is obtained by reducing a hexavalent molybdenum compound with a reducing agent, and then reacting the resulting with an acidic phosphate after neutralization with a mineral acid.

Abstract: A lubricating oil additive capable of providing an antioxidant which enables a lubricating oil composition to have long drain intervals, while reducing specific components such as metals and phosphorus atoms, and a lubricating oil composition containing the lubricating oil additive are provided. A phosphorus molybdenum compound represented by the following general formula (1) where R1, R2, and R3 each independently represent a hydrocarbon group having 1 to 20 carbon atoms is also provided.

Abstract: An electrophoretic particle salt that includes a cationic electrophoretic particle and an anionic group ionically associated with the cationic electrophoretic particle is employed in an electrophoretic display. A spacer group chemically bonds a cationic moiety to a surface of the electrophoretic particle. A method of making the electrophoretic particle salt includes particle surface modification, nucleophilic substitution to create an interim salt and anion exchange. The electrophoretic particle salt has an ionization constant that favors dissociation into a positively charged electrophoretic particle and the anionic group in a nonpolar medium. The electrophoretic display includes a pair of electrodes and a dispersion of the electrophoretic particle salt in a nonpolar medium in a gap between the pair of electrodes.

Abstract: There is provided a method of producing a rare earth salt of a dialkyl phosphate or a rare earth salt of dioleyl phosphate of a high purity useful as a polymerization catalyst of a conjugated diene compound by directly reacting a rare earth oxide or a rare earth hydroxide with a dialkyl phosphate or dioleyl phosphate of a high purity. In the invention, the rare earth oxide or rare earth hydroxide is reacted with the dialkyl phosphate or dioleyl phosphate of a high purity in a non-polar solvent in the presence of at least one compound selected from a halogenated hydroacid, phosphorous acid and a rare earth halide made from the same element as in an objective product as a catalyst.

Abstract: Disclosed are inorganic nanoparticles comprising a body comprising cadmium and/or zinc crystallized with selenium, sulfur, and/or tellurium; a multiplicity of phosphonic acid ligands comprising at least about 20% of the total surface ligand coverage; wherein the nanocrystal is capable of absorbing energy from a first electromagnetic region and capable of emitting light in a second electromagnetic region, wherein the maximum absorbance wavelength of the first electromagnetic region is different from the maximum emission wavelength of the second electromagnetic region, thereby providing a Stokes shift of at least about 20 nm, wherein the second electromagnetic region comprises an at least about 100 nm wide band of wavelengths, and wherein the nanoparticle exhibits has a quantum yield of at least about 10%. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A lubricant additive produced by the process comprising mixing an organophosphate and an organofluorine compound and reacting the organophosphate and the organofluorine compound to produce a reaction mixture comprising the lubricant additive. Also, a lubricant produced by the process comprising forming a reaction mixture by reacting an organophosphate and an organofluorine and adding at least a portion of the reaction mixture to a lubricant base.

Abstract: A process for preparing a rare-earth organophosphate in the form of a gel that can be used as is for the preparation of a “preformed” catalyst system intended, in particular, for the cis-1,4 stereospecific polymerization of conjugated dienes.

Abstract: The present invention relates to a zwitterionic stationary phase comprising a carrier and at least one zwitterionic ligand bound to said carrier, said phase being suitable for HPLC separation in Hydrophilic Interaction mode, wherein the positively charged part of said zwitterionic ligand is located at the end of the ligand, and the negatively charged part of said zwitterionic ligand is located between the positively charged part and the part of said zwitterionic ligand directly binding to said carrier, or a polymeric backbone attached to the carrier, wherein the intramolecular distance between the negatively charged part of the zwitterionic ligand preferably is at most 10 atoms long. The invention also provides methods for producing said zwitterionic stationary phase and method for using the phase in HPLC separations.

Abstract: Solutions of rare-earth organophosphates in an organic solvent are prepared by reacting, in such solvent, a rare-earth compound selected from among the rare-earth oxides, hydroxides, carbonates and hydroxycarbonates with an organophosphorus acid and in the presence of a reaction promoter selected from among water, nitric, hydrochloric, acetic, formic and propionic acids and the rare-earth salts of these acids; utilizing a reaction promoter simplifies the method, reduces the reaction time and provides a solution in which the residual solids content may be low.

Abstract: Disclosed are novel MRI contrast agents and imaging methods using the same. The novel MRI contrast agent comprises a chelating molecule with at least two phosphate groups coordinated with at least one paramagnetic substances.

Abstract: There is provided a method of producing a rare earth salt of a dialkyl phosphate or a rare earth salt of dioleyl phosphate of a high purity useful as a polymerization catalyst of a conjugated diene compound by directly reacting a rare earth oxide or a rare earth hydroxide with a dialkyl phosphate or dioleyl phosphate of a high purity. In the invention, the rare earth oxide or rare earth hydroxide is reacted with the dialkyl phosphate or dioleyl phosphate of a high purity in a non-polar solvent in the presence of at least one compound selected from a halogenated hydroacid, phosphorous acid and a rare earth halide made from the same element as in an objective product as a catalyst.

Abstract: A lubricant additive produced by various processes, including mixing an organophosphate and an organofluorine compound, reacting an organophosphate and an organofluorine compound, reacting a fluorinated organophosphate and an organofluorine compound (with or without molybendum disulfide), or reacting an organophosphate, a metal halide and an organofluorine compound (with or without molybendum disulfide), to produce a reaction mixture comprising the lubricant additive. Also, a lubricant produced by various processes, including mixing an organophosphate and an organofluorine compound, reacting an organophosphate and an organofluorine compound, reacting a fluorinated organophosphate and an organofluorine compound (with or without molybendum disulfide), or reacting an organophosphate, a metal halide and an organofluorine compound (with or without molybendum disulfide), and adding at least a portion of the reaction mixture to a lubricant base.

Abstract: A lubricating oil additive capable of providing an antioxidant which enables a lubricating oil composition to have long drain intervals, while reducing specific components such as metals and phosphorus atoms, and a lubricating oil composition containing the lubricating oil additive are provided. A phosphorus molybdenum compound represented by the following general formula (1) where R1, R2, and R3 each independently represent a hydrocarbon group having 1 to 20 carbon atoms is also provided.

Abstract: Provided is a phosphorus molybdenum amine compound, represented by the following general formula (1). where R1 to R6 each independently represent a hydrogen atom or a hydrocarbon group and p represents a number of 1 to 5, provided that all of R1 to R6 are can not all be hydrogen atoms at the same time and the phosphorus molybdenum compound is obtained by reducing a hexavalent molybdenum compound with a reducing agent, and then reacting the resulting with an acidic phosphate after neutralization with a mineral acid.

Abstract: A compound of Formula 1 Rf-A-OP(O)(O?M+)(O—RH) ??Formula 1 wherein Rf is a C2 to C6 linear or branched perfluoroalkyl optionally interrupted by one, two or three ether oxygen atoms; A is (CH2CF2)m(CH2)n—, (CH2)oSO2N(CH3)(CH2)p—, O(CF2)q(CH2)r—, or OCHFCF2OE-; m is 1 to 4; n, o, p, and r are each independently 2 to 20; q is 2; E is a C2 to C20 linear or branched alkyl group optionally interrupted by oxygen, sulfur, or nitrogen atoms; a cyclic alkyl group, or a C6 to C10 aryl group; M is a Group I metal or an ammonium cation (NHxR2y)+ wherein R2 is a C1 to C4 alkyl, x is 1 to 4, y is 0 to 3 and x+y is 4; and RH is a C1 to C20 linear, branched, or cyclic alkyl, or a C6 to C10 aryl, and its use as a surfactant is disclosed.

Abstract: The present invention relates to a phosphorylated glyceryl ether aluminum salt represented by the general formula (1): (wherein R1 represents an alkyl or an alkenyl group with 8 to 32 carbon atoms; R2 represents a hydrogen atom, a phosphoric acid residue or —CH2CH(OR2)CH2OR1 (wherein R1 and R2 are the same as described above, provided that a repeated binding number is 4 at the most when R2 is —CH2CH(OR2)CH2OR1); X1 represents a hydrogen atom or a phosphoric acid residue, and at least one of X1 and R2 is a phosphoric acid residue; Y represents an alkali metal atom or an alkaline earth metal atom; m represents a number from 0.3 to 1, and n represents a number from 0 to 1), and an external dermatological agent containing the same. The compound has benefits such as an excellent pore contracting activity and also a good solubility in oil.

Abstract: Bisphosphonate compounds are disclosed, particularly bisphosonate conjugates useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis.

Abstract: Stable rare earth tris (organophosphate) solutions comprise a rare earth tris (organophosphate) and a hydrocarbon solvent. From about 2% to about 10% rare earth element, preferably from about 3% to about 8%, is present in the solutions. The rare earth tris (organophosphate) solutions are stable from precipitation of the rare earth tris (organophosphate) for at least about fifteen (15) days, preferably for at least about twenty (20) days and most preferably at least about thirty (30) days. A process for preparing these solutions is described herein. A stabilizing additive, acid, glycol or mixtures thereof, is utilized to inhibit precipitation. The molar ratios of free acid, glycol and/or water to the rare earth element are controlled to inhibit precipitation.

Abstract: The present invention relates to the syntheses and structural elucidation of Combretastatin A1-Phosphate Prodrugs and Combretastatin B1-Phosphate Prodrugs and the utilization of those prodrugs in the treatment of neoplastic diseases. The prodrugs described herein have the structure: Combretastin A-1 Phosphate Prodrug (I) and Combretastin B-1 Phosphate Prodrug (II).

Abstract: A building material is formed from a specific composition containing a phosphoric ester compound represented by the following formulae (8)-c and (8)-d and copper ions, in a resin plate.

Abstract: Lubricants are taught that can quickly and easily form a lubricating layer on a metal surface of a metal before plastic processing. Such lubricants preferably include a primary lubricating agent or component having a bridge complex that satisfies the following conditions: (1) the complex contains at least two central metal atoms; (2) at least one first multidentate ligand forms a bridge between two central metal atoms; and (3) at least one second multidentate ligand is bound to at least one central metal atom and has at least one coordinating atom that can coordinate with metal atoms, but which is not coordinated with any of the central metal atoms or is only partially coordinated with at least one of those central metal atoms. A third multidentate ligand is preferably also bound to one of the central metal atoms and may preferably include at least two sulfur atoms that are coordinated to the central metal atom.

Abstract: A building material is formed from a specific composition containing a phosphoric ester compound represented by the following formulae (8)-c and (8)-d and copper ions, in a resin plate.

Abstract: A new crystalline maganese phosphate composition having an empirical formula: Mn3(PO4)4.2(H3NCH2CH2)3N.6(H2O). The compound was determined to crystallize in the trigonal space group P-3c1 with a=8.8706(4) Å, c=26.1580(2) Å, and V (volume)=1783 Å3. The structure consists of sheets of corner sharing Mn(II)O4 and PO4 tetrahedra with layers of (H3NCH2CH2)3N and water molecules in-between. The pronated (H3NCH2CH2)3N molecules provide charge balancing for the inorganic sheets. A network of hydrogen bonds between water molecules and the inorganic sheets holds the structure together.

Abstract: Stable rare earth tris (organophosphate) solutions comprise a rare earth tris (organophosphate) and a hydrocarbon solvent. From about 2% to about 10% rare earth element, preferably from about 3% to about 8%, is present in the solutions. The rare earth tris (organophosphate) solutions are stable from precipitation of the rare earth tris (organophosphate) for at least about fifteen (15) days, preferably for at least about twenty (20) days and most preferably at least about thirty (30) days. A process for preparing these solutions is described herein. A stabilizing additive, acid, glycol or mixtures thereof, is utilized to inhibit precipitation. The molar ratios of free acid, glycol and/or water to the rare earth element are controlled to inhibit precipitation.

Abstract: A compound capable of efficiently cutting off light in the near infrared region, copper (meth)acryloyloxyethyl phosphate coordination complex, is synthesized including reacting (meth)acryloyloxyethyl phosphate and copper acetate monohydrate in water.

Abstract: The invention relates to a method for separating and recovering rhodium from reaction products of oxosynthesis, especially reaction products containing cobalt. The invention also relates to the reuse of rhodium as a catalyst for hydroformulation and to a catalyst for hydroformulation itself. The inventive method is characterized by the following: extraction of the organic solution with an aqueous phosphate solution or a phosphate solution, water washing, oxidative treatment of the organic phase, and extraction of the organic phase with an aqueous water-soluble arylphosphine solution.

Abstract: Disclosed are thiol-functionalized phospholipids that have been covalently linked to a gold and/or silver substrate, methods for making them, and intermediates useful for such purposes. The resulting material creates a biomimetic surface that can be included in a conduit containing blood.

Abstract: By forming a copper salt of phytic acid at a molar ratio of copper ion (Cu2+) to phytic acid of 2:1 or higher, there is provided a compound absorbing near infrared rays, which does not substantially absorb lights of visible light wavelength range, but strongly absorb lights of near infrared wavelength range, and shows extremely good water solubility.

Abstract: An organometallic compound suitable for use as a catalyst for the preparation of an ester comprises the reaction product of an orthoester or condensed orthoester of titanium, zirconium or aluminum, an alcohol containing at least two hydroxyl groups, an organophosphorus compound containing at least one P—OH group and a base. A process for the preparation of an ester comprises carrying out an esterification reaction in the presence of the catalyst In a further embodiment the organometallic compound suitable for use as a catalyst in an esterification process comprises the reaction product of, in addition, a 2-hydroxy carboxylic acid.

Abstract: A molybdated dispersant composition represented by the formula: (R1—NR2R3H+)m−nXn(MoHPA)m− provides good friction properties to lubricants. In the formula, R1—NR2R3 represents an amine-containing dispersant, R1 is a group providing dispersant properties to said dispersant composition, each of R2 and R3 is independently hydrogen, a hydrocarbyl group, or an additional R1 group; X is hydrogen, a monovalent metal ion, a single valence of a polyvalent metal ion, an ammonium ion, or an amine cation, m is 3 or 4, n is 0 to about 2.5 when m is 3 and 0 to about 3.5 when m is 4, and (MoHPA)m− is a molybdenum heteropolyacid anion of charge m.

Abstract: The invention can relate to lithium salts of the general formula (I)

Abstract: Phospholipid derivatives containing higher elements of the Vth main group (P, As, Sb, Bi), their method of preparation and antineoplastic and antimicrobially active medications that can be prepared from the phospholipid derivatives.

Abstract: Readily processible cluster compositions of vanadium and phosphorus are precursors to vanadium-phosphorus catalysts including vanadyl pyrophosphate and vanadylbis(metaphosphate).